KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12V	Spindle Cell Sarcoma	KRAS G12V	Spindle Cell Sarcoma	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KRAS G12V	Hepatocellular Cancer	KRAS G12V	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	avutometinib Sensitive: C3 – Early Trials avutometinib Sensitive : C3	avutometinib Sensitive: C3 – Early Trials avutometinib Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3

KRAS G12V

Associations